Search results
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 months agoImage source: The Motley Fool. Gilead Sciences (NASDAQ: GILD) Q4 2023 Earnings Call Feb 06, 2024,...
The Gilead Sciences Inc (GILD) Company: A Short SWOT Analysis
GuruFocus.com via Yahoo Finance· 7 months agoRobust product sales growth, with a focus on infectious diseases, cardiovascular diseases, and...
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals,...
Zacks via Yahoo Finance· 6 months agoFor Immediate Release Chicago, IL – November 24, 2023 – Today, Zacks Equity Research discusses...
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education...
ACCESSWIRE via Yahoo Finance· 2 years agoGilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating...
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Zacks via Yahoo Finance· 2 years agoGilead (GILD) delivered earnings and revenue surprises of 31.94% and 15.06%, respectively, for the...
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 28, 2022 – Today, Zacks Equity Research discusses...
Q1 2024 Gilead Sciences Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 month agoParticipants Andrew D. Dickinson; CFO; Gilead Sciences, Inc. Cindy Perettie; EVP of Kite; Gilead Sciences, Inc. Daniel P. O'Day; Chairman & CEO; Gilead Sciences, Inc. Jacquie Ross; VP of IR; ...
2 Biotech Stocks That Could Make You Richer
Motley Fool· 1 year agoThe biotech industry is a great place to look for such companies. Let's look at two biotech stocks that could help make investors richer in the years...
Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years
Investor's Business Daily· 1 year agoGilead Sciences followed up a strong quarterly report with a third Food and Drug Administration...
Gilead's Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
Benzinga via Yahoo Finance· 2 years agoGilead Sciences Inc (NASDAQ: GILD) announced results reinforcing Biktarvy...
